Development and in-vitro evaluation of the extended release valsartan from sericin and alginate beads

Development and in-vitro evaluation of the extended release valsartan from sericin and alginate beads

Emanuelle D. Freitas, Renata B. da Silva, Sara R. Deldotti, Gabrielly A. Marzola, Meuris G. C. da Silva, Melissa G. A. Vieira

ARTIGO

Inglês

Valsartan, a type 1 selective receptor for angiotensin, is primarily used in the treatment of hypertension and, in a minority, to treat coronary artery disease and heart failure. Among its adverse effects, it can be mentioned malaise, dizziness and headache. Furthermore, in the conventional form of...

CONSELHO NACIONAL DE DESENVOLVIMENTO CIENTÍFICO E TECNOLÓGICO - CNPQ

FUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULO - FAPESP

Fechado

Development and in-vitro evaluation of the extended release valsartan from sericin and alginate beads

Emanuelle D. Freitas, Renata B. da Silva, Sara R. Deldotti, Gabrielly A. Marzola, Meuris G. C. da Silva, Melissa G. A. Vieira


										

Development and in-vitro evaluation of the extended release valsartan from sericin and alginate beads

Emanuelle D. Freitas, Renata B. da Silva, Sara R. Deldotti, Gabrielly A. Marzola, Meuris G. C. da Silva, Melissa G. A. Vieira

    Fontes

    Chemical engineering transactions

    Vol. 74 (May., 2019), p. 1537-1542